PHARMACY

Teva launches generic version of Astellas’ Adenoscan

BY Alaric DeArment

JERUSALEM — Teva Pharmaceutical Industries has become the first to launch a generic drug for treating certain heart patients, the company said.

Teva announced the launch of adenosine injection, a generic version of Astellas Pharma’s Adenoscan. The drug is used in combination with thallium-201 in patients undergoing myocardial perfusion scintigraphy who are unable to exercise adequately.

Adenoscan had sales of $65 million during the 12-month period ended in June, according to IMS Health. As the first company to file for approval of the generic, Teva has 180 days in which to market the generic exclusively, according to Food and Drug Administration regulations.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Cancer organizations see big uptick in health insurance marketplace usage by decade’s end

BY Alaric DeArment

WASHINGTON — Next year, 7 million people will be using health insurance marketplaces, and that figure will nearly quadruple in five years, according to a coalition of cancer-focused organizations.

Patient Services Inc., which includes 18 partnering cancer and patient advocacy organizations, announced Wednesday the launch of the Cancer Insurance Checklist, designed to help people with cancer, a history of the disease or those at risk of getting it, choose insurance plans in the state-based health insurance marketplaces, which will open on Oct. 1.

According to PSI, by the end of the decade, 27 million people will be in health insurance marketplaces, and PSI said the checklist would empower thousands of people whose lives have been influenced by cancer amid the implementation of the Patient Protection and Affordable Care Act. The checklist guides consumers to review the coverage within each insurance plan they are considering, including coverage for services provided by their healthcare team, where care is delivered, medications and various common cancer treatments and services they may need.


Get connected and follow us on LinkedIn for the most in-depth coverage of drug store news. Join the conversation.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Mylan seeks approval for generic fibromyalgia drug

BY Alaric DeArment

PITTSBURGH — Mylan is challenging the patent protection on a drug used to treat fibromyalgia, prompting a lawsuit from the branded drug’s manufacturers.

Mylan said Wednesday that Forest Labs and Royalty Pharma had sued it in the U.S. District Court for the District of Delaware in connection with its filing of a regulatory approval application with the Food and Drug Administration for milnacipran hydrochloride tablets in the 12.5-mg, 25-mg, 50-mg and 100-mg strengths. The drug is a generic version of Savella.

If Mylan is the first company to successfully file an approval application with the FDA for a generic version of Savella, it will receive 180 days of market exclusivity in which to compete directly with Forest following FDA approval.

Savella had sales of about $123 million during the 12-month period ended in June, according to IMS Health.


Get connected and follow us on LinkedIn for the most in-depth coverage of drug store news. Join the conversation.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?